AdAlta Schedules Investor Webinar on CAR-T Deal and ‘East to West’ Strategy

AdAlta Ltd. ( (AU:1AD) ) just unveiled an update.

AdAlta will host a virtual investor webinar on 15 January 2026 to update the market on its recently announced collaboration between its subsidiary AdCella and Shanghai Cell Therapy Group to develop BZDS1901, an armoured CAR-T cell therapy for mesothelioma and other solid tumours, for global markets. The session, led by CEO Tim Oldham, will also outline next steps in advancing the company’s ‘East to West’ cellular immunotherapy strategy and financing plans for AdCella, providing investors with further insight into how this high-profile CAR-T transaction may accelerate AdAlta’s expansion in solid cancer immunotherapies and strengthen its position within the fast-growing global cell therapy market.

The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.

More about AdAlta Ltd.

AdAlta Limited is an ASX-listed, clinical-stage biotechnology company focused on developing effective cellular immunotherapies for solid cancers, a market that remains underserved despite accounting for the majority of cancer cases. Through its ‘East to West’ strategy, the company in-licenses differentiated T cell therapy products from Asian innovators and advances them through FDA-regulated manufacturing and early-phase clinical trials in Australia, with the aim of on-licensing to larger biopharmaceutical partners. AdAlta is targeting the rapidly growing cellular immunotherapy segment, projected to reach US$20.3 billion by 2028, and also holds a partnering-ready, first-in-class fusion protein, AD-214, for fibrotic lung and kidney diseases such as idiopathic pulmonary fibrosis.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$13.77M

Find detailed analytics on 1AD stock on TipRanks’ Stock Analysis page.